Income Tax Expense (Benefit) in USD of Vanda Pharmaceuticals Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Vanda Pharmaceuticals Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2010 to Q3 2025.
  • Vanda Pharmaceuticals Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was -$5.8M, a 531% decline year-over-year.
  • Vanda Pharmaceuticals Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was -$22.9M, a 1252% decline year-over-year.
  • Vanda Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2024 was -$4.02M, a 205% decline from 2023.
  • Vanda Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2023 was $3.83M, a 23.8% decline from 2022.
  • Vanda Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2022 was $5.03M, a 45.5% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

Vanda Pharmaceuticals Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$22.9M -$5.8M -$4.88M -531% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-30
Q2 2025 -$18.1M -$7.68M -$6.68M -670% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-31
Q1 2025 -$11.4M -$7.87M -$7.36M -1420% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 -$4.02M -$1.59M -$2.32M -314% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-14
Q3 2024 -$1.7M -$920K -$663K -258% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-30
Q2 2024 -$1.03M -$998K -$2.07M -193% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-31
Q1 2024 $1.04M -$518K -$2.79M -123% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $3.83M $739K -$2.01M -73.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-14
Q3 2023 $5.84M -$257K -$2.45M -112% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $8.29M $1.07M -$144K -11.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $8.44M $2.28M +$3.41M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $5.03M $2.75M +$1.22M +79.6% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-14
Q3 2022 $3.81M $2.19M -$760K -25.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $4.57M $1.22M -$1.74M -58.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-28
Q1 2022 $6.3M -$1.13M -$2.91M -164% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $9.21M $1.53M -$1.2M -44% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-08
Q3 2021 $10.4M $2.95M +$497K +20.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $9.92M $2.95M +$576K +24.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $9.34M $1.78M +$1.02M +135% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $8.32M $2.73M +$1.14M +71.5% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-09
Q3 2020 $7.18M $2.45M +$90.6M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$83.4M $2.38M +$2.36M +13094% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$85.8M $755K +$745K +7450% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$86.5M $1.59M +$1.64M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$88.2M -$88.1M -$88.2M -95912% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-29
Q2 2019 $78K $18K -$72K -80% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $150K $10K +$12K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $138K -$42K -$129K -148% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-11
Q3 2018 $267K $92K +$69K +300% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $198K $90K +$83K +1186% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $115K -$2K -$21K -111% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-03
Q4 2017 $136K $87K -$17K -16.3% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $153K $23K +$23K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $130K $7K +$7K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $123K $19K +$19K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-02
Q4 2016 $104K $104K +$104K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-19
Q3 2016 $0 $0 $0 Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-03
Q2 2016 $0 $0 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2016-07-28
Q1 2016 $0 $0 $0 Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-05
Q4 2015 $0 $0 Oct 1, 2015 Dec 31, 2015 10-K 2017-02-17
Q3 2015 $0 Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $0 Apr 1, 2015 Jun 30, 2015 10-Q 2016-07-28
Q1 2015 $0 Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2011 -$444K -$286K Oct 1, 2011 Dec 31, 2011 10-K 2014-02-25
Q3 2011 -$113K +$2.17M +95.1% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-08
Q2 2011 -$51K -$14K -37.8% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-03
Q1 2011 $6K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-09
Q3 2010 -$2.29M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 -$37K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05

Vanda Pharmaceuticals Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$4.02M -$7.85M -205% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-14
2023 $3.83M -$1.2M -23.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-14
2022 $5.03M -$4.19M -45.5% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-14
2021 $9.21M +$894K +10.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-08
2020 $8.32M +$94.8M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-09
2019 -$86.5M -$86.7M -62799% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $138K +$2K +1.47% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $136K +$32K +30.8% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $104K +$104K Jan 1, 2016 Dec 31, 2016 10-K 2019-02-19
2015 $0 $0 Jan 1, 2015 Dec 31, 2015 10-K 2017-02-17
2014 $0 $0 Jan 1, 2014 Dec 31, 2014 10-K 2017-02-17
2013 $0 Jan 1, 2013 Dec 31, 2013 10-K 2016-02-12
2011 -$444K -$2.52M -121% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-25
2010 $2.08M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.